MedTrace Logo

Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin

NCT02382068 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-11-09

No results posted yet for this study

Summary

This randomized pilot clinical trial studies dexamethasone in preventing hearing loss in patients receiving cisplatin. Injecting a steroid, such as dexamethasone, behind the eardrum before chemotherapy may help protect against cisplatin-associated hearing loss.

Conditions

  • Malignant Neoplasm
  • Ototoxicity

Interventions

DRUG

Dexamethasone

Given via intratympanic injection

OTHER

Placebo

Given via intratympanic injection

DRUG

Cisplatin

Standard of care treatment with the following treatment course criteria: 1. Dose: \> 50 mg/m2 2. Frequency: q3 -q4 weeks 3. Cycles: 7 maximum

Sponsors & Collaborators

  • Aaron Moberly

    lead OTHER

Principal Investigators

  • Aaron Moberly, MD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2017-07-31
Completion
2017-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02382068 on ClinicalTrials.gov